|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Quality of life in patients with minimal hepatic encephalopathy显示文摘Minimal hepatic encephalopathy(MHE) represents the mildest type of hepatic encephalopathy(HE). This condition alters the performance of psychometric tests by impairing attention, working memory, psychomotor speed, and visuospatial ability, as well as electrophysiological and other functional brain measures. MHE is a frequent complication of liver disease, affecting up to 80% of tested patients, depending of the diagnostic tools used for the diagnosis. MHE is related to falls, to an impairment in fitness to drive and the development of overt HE, MHE severely affects the lives of patients and caregivers by altering their quality of life(QoL) and their socioeconomic status. MHE is detected in clinically asymptomatic patients through appropriate psychometric tests and neurophysiological methods which highlight neuropsychological alterations such as video-spatial orientation deficits, attention disorders, memory, reaction times, electroencephalogram slowing, prolongation of latency evoked cognitive potentials and reduction in the critical flicker frequency. Several treatments have been proposed for MHE treatment such as non-absorbable disaccharides, poorly absorbable antibiotics such rifaximin, probiotics and branched chain amino acids. However, because of the multiple diagnosis methods, the various endpoints of treatment trials and the variety of agents used in trials, to date the treatment of MHE is not routinely recommended apart from on a case-by-case basis. Aim of this review is analyze the burden of MHE on QoL of patients and provide a brief summary of therapeutic approaches. | Lorenzo Ridola Silvia Nardelli Stefania Gioia Oliviero Riggio | 2018 | World Journal of Gastroenterology2018，24，48： | 14 |
| 2 | Spontaneous porto-systemic shunts in liver cirrhosis:Clinical and therapeutical aspects显示文摘Spontaneous porto-systemic shunts(SPSS)are frequent in liver cirrhosis and their prevalence increases as liver function deteriorates,probably as a consequence of worsening portal hypertension,but without achieving an effective protection against cirrhosis'complications.Several types of SPSS have been described in the literature,each one associated with different clinical manifestations.In particular,recurrent or persistent hepatic encephalopathy is more frequent in patients with splenorenal shunt,while the presence of gastric varices and consequently the incidence of variceal bleeding is more common in gastrorenal shunt.In the advanced stage,the presence of large SPSS can lead to the so called“portosystemic shunt syndrome”,characterized by a progressive deterioration of hepatic function,hepatic encephalopathy and,sometimes,portal vein thrombosis.The detection of SPSS in patients with liver cirrhosis is recommended in order to prevent or treat recurrent hepatic encephalopathy or variceal bleeding. | Silvia Nardelli Oliviero Riggio Stefania Gioia Marta Puzzono Giuseppe Pelle Lorenzo Ridola | 2020 | World Journal of Gastroenterology2020，26，15： | 11 |
| 3 | Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy显示文摘Minimal hepatic encephalopathy (MHE) represents the mildest type of hepatic encephalopathy (HE). MHE is considered as a preclinical stage of HE and is part of a wide spectrum of typical neurocognitive alterations characteristic of patients with liver cirrhosis, particularly involving the areas of attention, alertness, response inhibition, and executive functions. MHE can be detected by testing the patients’ psychometric performance, attention, working memory, psychomotor speed, and visuospatial ability, as well as by means of electrophysiological and other functional brain measures. MHE is very frequent, affecting from 20% up to 80% of patients tested, depending of the diagnostic tools used. Although subclinical, MHE is considered to be clinically relevant. In fact, MHE has been related to the patients’ falls, fitness to drive, and working ability. As a consequence, MHE affects the patients and caregivers lives by altering their quality of life and even their socioeconomic status. Recently sarcopenia, a very common condition in patients with advanced liver disease, has been shown to be strictly related to both minimal and overt HE. Aim of this review is to summarize the most recently published evidences about the emerging relationship between sarcopenia and cognitive impairment in cirrhotic patients and provide suggestions for future research. | Silvia Nardelli Stefania Gioia Jessica Faccioli Oliviero Riggio Lorenzo Ridola | 2019 | World Journal of Gastroenterology2019，25，35： | 4 |
| 4 | Cirrhotic Patients Are at Risk for Health Care–Associated Bacterial Infections显示文摘 | Manuela Merli Cristina Lucidi Valerio Giannelli Michela Giusto Oliviero Riggio Marco Falcone Lorenzo Ridola Adolfo Francesco Attili Mario Venditti | 2010 | Clinical Gastroenterology and Hepatology2010，，11： | 3 |
| 5 | Hepatic encephalopathy therapy:An overview显示文摘Type-C hepatic encephalopathy(HE) is a severe complication of cirrhosis,which seriously affects quality of life and is strongly related to patient survival.Treatment based on a classical pharmacological approach that is aimed at reducing the production of gut-derived toxins,such as ammonia,is still under debate.Currently,results obtained from clinical trials do not support any specific treatment for HE and our competence in testing old and new treatment modalities by randomized controlled trials with appropriate clinically relevant end-points urgently needs to be improved.On the other hand,patients who are at risk for HE are now identifiable,based on studies on the natural history of the disease.Today,very few studies that are specifically aimed at establishing whether HE may be prevented are available or in progress.Recent studies have looked at non absorbable disaccharides or antibiotics and other treatment modalities,such as the modulation of intestinal flora.In the treatment of severe stage HE,artificial liver supports have been tested with initial positive results but more studies are needed. | Oliviero Riggio Lorenzo Ridola Chiara Pasquale | 2010 | World Journal of Gastrointestinal Pharmacology and Therapeutics2010，1，2： | 2 |
| 6 | Safety of cold polypectomy for < 10 mm polyps at colonoscopy: a prospective multicenter study显示文摘 | A. Repici C. Hassan E. Vitetta E. Ferrara G. Manes G. Gullotti A. Princiotta P. Dulbecco N. Gaffuri E. Bettoni N. Pagano G. Rando G. Strangio A. Carlino F. Romeo D. de Paula Pessoa Ferreira A. Zullo L. Ridola A. Malesci | 2012 | Endoscopy2012，，01： | 2 |
| 7 | Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis?显示文摘Porto sinusoidal vascular liver disease (PSVD) and portal vein thrombosis (PVT) are distinct vascular liver diseases characterized, respectively, by an intrahepatic and a prehepatic obstacle to the flow in the liver portal system. PVT may also occur as a complication of the natural history of PSVD, especially if a prothrombotic condition coexists. In other cases, it is associated to local and systemic pro-thrombotic conditions, even if its cause remains unknown in up to 25% despite an active search. In our opinion, the presence of PSVD should be suspected in patients with PVT especially in those with PVT “sine causa” and the active search of this condition should be included in their diagnostic work-out. However, sometimes the diagnosis of pre-existing PSVD is very hard. Biopsy cannot be fully discriminant as similar histological data have been described in both conditions. Liver stiffness may help as it has been shown to be higher in PSVD than in “pure” PVT, due to the presence of sclerosis in the portal venous radicles observable in PSVD patients. Nevertheless, comparing liver stiffness between PVT and PSVD has until now been restricted to very limited series of patients. In conclusion, even if it is still totally hypothetical, our point of view may have clinical consequences, especially when deciding to perform a liver biopsy in patients with a higher liver stiffness and suspending the anticoagulation in patients with PVT and no detectable prothrombotic factors. | Stefania Gioia Silvia Nardelli Lorenzo Ridola Giulia d’Amati Oliviero Riggio | 2019 | World Journal of Hepatology2019，11，8： | 2 |
| 8 | Rifaximin therapy and hepatic encephalopathy:Pros and cons显示文摘Hepatic encephalopathy(HE) is the second most common major complication in cirrhotics and it significantly impacts quality of life.Therapeutic approaches for HE treatment and prevention mainly continue to rely on ammonia-lowering strategies and non-absorbable disaccharides are currently considered the cornerstone therapy.Non-absorbable antibiotics,such as neomycin and paramomycin,are effective in treatment of acute HE episodes but their prolonged use for recurrence prevention is hampered by possible side-effects.To overcome these limitations,rifaximin use has been proposed.Rifaximin has been shown to be not superior to non-absorbable disaccharides for either HE treatment or prevention,with a similar incidence of side-effects.Cirrhosis significantly increases rifaximin absorption and this could be a cause for concern.Following long-term rifaximin therapy,Clostridium difficile colitis has been observed and Candida albicans has been isolated from 20% of patients.In addition,selection of resistant mutants of both Gram-negative and-positive bacteria in the gastrointestinal tract cannot be definitely ruled out.Electrolyte alterations(sodium and potassium) have been reported during rifaximin therapy,a warning for its long-term use in cirrhotics.Moreover,a potential interference with vitamin K production should be considered which could further impair the already altered clotting status of these patients.The therapeutic cost of rifaximin is markedly higher than non-absorbable disaccharides.While waiting for further safety data,caution should be used to limit the use of rifaximin therapy for a very short-term period in selected HE cirrhotics not responding to nonabsorbable disaccharides. | Angelo Zullo Cesare Hassan Lorenzo Ridola Roberto Lorenzetti Salvatore MA Campo Oliviero Riggio | 2012 | World Journal of Gastrointestinal Pharmacology and Therapeutics2012，3，4： | 2 |
| 9 | CIinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial显示文摘 | Riggio O Ridola L Angeloni S | 2010 | J Hepatol2010，53，2： | 1 |
| 10 | Candida infections in children treated with conventional chemotherapy for solid tumors (transplant recipients excluded ): The Institut Gustave Roussy Pediatrics Department experience 显示文摘 | V Ridola Echachaty G Raimondo | 2004 | Pediatric Blood Cancer2004，42，4： | 1 |
| 11 | Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt显示文摘 | Oliviero Riggio Silvia Nardelli Federica Moscucci Chiara Pasquale Lorenzo Ridola Manuela Merli | 2012 | Clinics in Liver Disease2012，，1： | 1 |
| 12 | Candida infections in children treated with conventional chemotherapy for solid tumor (transplant recipients excluded): The Institute Gustave Roussy Pediatric Department experience显示文摘 | Ridola V Chachaty E Raimondo C | 2004 | Pediatr Blood Cancer2004，42，4： | 1 |
| 13 | High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradia- tion for local meduHoblastom recurrence or progression after conventional chemotherapy 显示文摘 | Ridola V Grill J Doz F | 2007 | Cancer2007，110，1： | 1 |
| 14 | High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication : a proof of concept study 显示文摘 | Zullo A Ridola L Francesco VD | 2015 | Ann Gastroenterol2015，28，4： | 1 |
| 15 | Palma A Functional anatomy and imaging of the foot显示文摘 | Ridola C | 2001 | ital J Anat Embryol2001，106，2： | 1 |
| 16 | Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms显示文摘BACKGROUND Alterations in health-related quality of life(HRQoL)and neuropsychological disorders were described in the hepatitis C virus(HCV)patients.Although several studies investigated the modifications of HRQoL after HCV eradication,no data exists on the modifications of neuropsychological symptoms.AIM To investigate the effect of directly acting antivirals(DAAs)treatment on HRQoL and neuropsychological symptoms.METHODS Thirty nine patients with HCV infection underwent a neuropsychological assessment,including Zung-Self Depression-Rating-Scale,Spielberg State-Trait Anxiety Inventory Y1-Y2 and the Toronto-Alexithymia Scale-20 items before and after DAAs treatment.HRQoL was detected by Short-Form-36(SF-36).RESULTS All HRQoL domains,but role limitation physical and bodily pain,significantly improved after treatment.Interestingly,after DAAs treatment,all domains of HRQoL returned similar to those of controls.Each neuropsychological test significantly improved after HCV eradication.A significant correlation was observed among each psychological test and the summary components of SF-36.At multiple linear regression analysis including each psychological test as possible covariates,Zung-Self Depression Rating Scale(Zung-SDS)score was independently and significantly related to summary components of the SF-36 in the basal state and the difference between Zung-SDS score before and after treatment was the only variable significantly and independently related to the modification of HRQoL induced by the treatment.CONCLUSION Neuropsychological symptoms strongly influenced HRQoL in HCV patients and there was a significant improvement of neuropsychological tests and HRQoL after DAAs treatment. | Silvia Nardelli Oliviero Riggio Davide Rosati Stefania Gioia Alessio Farcomeni Lorenzo Ridola | 2019 | World Journal of Gastroenterology2019，25，48： | 1 |
| 17 | Hepatic encephalopathy thera- py: An overview 显示文摘 | Riggio O Ridola L Pasquale C | 2010 | World J Gastrointest Pharmacol Ther2010，1，2： | 1 |
| 18 | Standard triple and sequential therapies for Helicobacter pylori eradication:An update显示文摘 | Zullo A Hassan C Ridola L | 2013 | European J Inter Med2013，24，1： | 1 |
| 19 | Functional anatomy and imaging of the foot 显示文摘 | Ridola C Palma A | 2001 | Ital J Anat Embryol2001，106，2： | 1 |
| 20 | Standard triple and sequential therapies for Helicobacter pylori eradication: An update显示文摘 | Angelo Zullo Cesare Hassan Lorenzo Ridola Vincenzo De Francesco Dino Vaira | 2013 | European Journal of Internal Medicine2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员